搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
10 天
Neurocrine停止开发luvadaxistat,因临床试验未达预期
SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX)今日宣布停止开发用于治疗与精神分裂症相关的认知障碍的luvadaxistat,原因是该化合物在ERUDITE二期临床研究中未能达到主要终点。此决定是在与先前显示出希望的INTERACT研究结果不一致后做出的。 ERUDITE试验未能重现先前的认知改善结果,这被归因于认知测量的显著变异性以及研 ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
今日热点
On running again in 2028
Hezbollah rockets hit Israel
Alabama mass shooting
Actress Crosby dies at 90
Donlon's homes searched
Ga. suspect's mom indicted
Pandas leaving for China
CAH sues for trespassing
J&J unit files for bankruptcy
Former WA governor dies
Released after guilty plea
To skip Al Smith dinner
House repeals emission rules
Drug price challenge revived
Beirut strike death toll
ISR raids Al Jazeera office
Daylight saving time
CA firefighter held for arson
San Francisco homelessness
Sesame Place suit verdict
TN abortion law blocked
Boeing defense chief exits
Biden hosts 'Quad' summit
Suns broadcaster dies
SC 1st execution in 13 years
FDA approves flu vaccine
ISR strike on Gaza school
CA bill to protect kids online
No. 1 at box office again
反馈